Compounds useful in the treatment of anthrax and inhibiting lethal factor
View Patent ↗This invention relates to compounds of formula (I), and a method for treating anthrax or inhibiting lethal factor by administrating a composition containing a compound of formula (I) and a pharmaceutically acceptable carrier. This invention further relates to the use of the compounds of formula (I) to treat other conditions related to an anthrax infection.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from the group consisting of C 6-10 aryl groups, said aryl groups optionally substituted with 1 to 3 groups of R a ;
R a is selected from the group consisting of C 1-6 alkyl and halogen groups; and
R is selected from the group consisting of C 3-10 heterocycloalkyl groups.
2. The compound according to claim 1 , wherein R 1 is a phenyl group optionally substituted with 1 to 3 groups of R a .
3. The compound according to claim 1 , wherein R 1 is a phenyl group substituted with 1 to 3 groups of halogen, methyl, ethyl, propyl, butyl, or a mixture thereof.
4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4′-tetrahydropyranyl) -acetamide;
compounds provided in Table 1 below
TABLE 1
Example #
R 1
R 2
64
74
78
105
130
and a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4 , wherein the compound is
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4′-tetrahydropyranyl) -acetamide;
or a pharmaceutically acceptable salt thereof.
6. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
7. A composition comprising a compound according to claim 4 and a pharmaceutically acceptable carrier.
8. A composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.